Announcement PDF Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/09/01 Amended 01/01/11 Name of entity: Microba Life Sciences Ltd ABN: 82 617 096 652 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director Ian Frazer Date of last notice 15 August 2025 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or indirect interest 1. Direct 2. Indirect 3. Indirect Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. 1. Ian Frazer 2. Frazer Services Pty Ltd as trustee for The Frazer Family Trust. Ian Frazer is a director and shareholder of Frazer Services Pty Ltd and a beneficiary of the Frazer Family Trust 3. HSBC Custody Nominees (Australia) Limited – A/C 2 – beneficiary Date of change 29 July 2026 No. of securities held prior to change 1. 277,778 Ordinary Shares. 2. 2,001,013 Ordinary Shares & 416,666 Options exercisable at $0.14, expiring 13 August 2027. 3. 389,444 Ordinary Shares. Class Ordinary Shares & Options Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Number acquired 1. Nil. 2. 200,000 Ordinary Shares and 200,000 Options exercisable at $0.0625, expiring 29 July 2029. 3. Nil. Number disposed Nil Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation $10,000, being $0.05 per Ordinary Share. The Options were issued for nil cash consideration on the basis of one free attaching Option for every one Ordinary Share subscribed for. No. of securities held after change 1. 277,778 Ordinary Shares. 2. 2,201,013 Ordinary Shares, 416,666 Options exercisable at $0.14, expiring 13 August 2027, and 200,000 Options exercisable at $0.0625, expiring 29 July 2029. 3. 389,444 Ordinary Shares. Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy- back Participation in Tranche 2 of the Placement announced to the ASX on 12 June 2026, approved by Shareholders under ASX Listing Rule 10.11 at the General Meeting held on 24 July 2026 (Resolutions 5(a) and 5(b)). Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed N/A Interest acquired N/A Interest disposed N/A Appendix 3Y Change of Director’s Interest Notice + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3 Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation N/A Interest after change N/A Part 3 – +Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A